Pharma Journalist -

The U.S. Food and Drug Administration (FDA) has accepted Kowa Pharmaceuticals America’s New Drug Application (NDA) for K-911, an investigational eye drop being developed to reduce…
Read More...

AusperBio Therapeutics has raised $120 million in a Series C financing round to support the development of its experimental treatments for chronic hepatitis B (CHB) and prepare its lead…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Priovant Therapeutics’ LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM), a rare autoimmune…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at…
Read More...

BioXcel Therapeutics has entered into an agreement with Teva Pharmaceuticals International GmbH for the sale of substantially all of its assets as the biotechnology company begins…
Read More...

The U.S. Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in children weighing at least 2 kg. The…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to ReviR Therapeutics’ investigational drug RTX-117 for the treatment of…
Read More...

The U.S. Food and Drug Administration (FDA) has approved two Ziihera (zanidatamab-hrii)-based treatment regimens for the first-line treatment of adults with unresectable locally…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ RASONQUE (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic adenocarcinoma…
Read More...

REGENXBIO has provided an update on RGX-121, its investigational gene therapy for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The company said it does not…
Read More...